proliferation through induction of AMP-activated protein kinase (AMPK), 14 and induction of autophagy through activating the p38 MAPK pathway. 12 However, the potential anticancer effects of resveratrol have rarely been investigated in canine cancer cells. To the best of our knowledge, there is only 1 study that reported the growth inhibitory effect of resveratrol and its synthetic oligomers against canine glioblastoma and histiocytic sarcoma cell lines. 15 The potential anticancer effects of resveratrol have not been determined in canine HSAs. Therefore, the objective of this study is to determine the growth inhibitory effects of resveratrol on HSA cell lines.
In the current work, resveratrol markedly inhibited the growth and induced apoptosis in 2 canine HSA cell lines, Frog and DD-1. Since doxorubicin is the standard-of-care anticancer for canine HSA, 16 we also determined the growth inhibitory effect of resveratrol when combined with doxorubicin. Interestingly, resveratrol significantly enhanced the growth inhibitory effect of doxorubicin when used in combination.
These findings suggest that resveratrol may have anticancer effects against canine HSA and could be a potential adjunct therapy to the standard-of-care anticancer drugs used in canine HSA patients.
| MATERIALS AND METHODS

| Materials
Ham's F12 medium and Dulbecco's modified Eagle's medium (DMEM) Chemiluminescence western blotting detection reagents, MemCode
Reversible Protein Stain Kit and bicinchoninic acid (BCA) protein assay were purchased from Thermo Pierce (Rockford, IL). Nitrocellulose membrane was purchased from Bio-Rad Laboratories (Hercules, CA). 21 and it corresponds to the peak plasma concentration of doxorubicin in canine cancer patients. 22 To determine the effect of resveratrol on HSA cells viability when combined with a wide range of doxorubicin concentrations, Frog cells were pre-treated with 50 μM resveratrol for 2 hours prior to the addition of 0.1 to 2 μM doxorubicin for an additional 22 hours. Stock doxorubicin solutions were prepared by dissolving doxorubicin in the appropriate serum-free medium.
| Cell culture
| Cell viability assay
Cell viability was determined by measuring the capacity of reducing enzymes present in viable cells to convert 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to formazan crystals as described previously. 23 Briefly, following drug treatment, the media were removed and 100 μL of serum-free media containing 1.2 mM MTT was added to each cell culture well. The plate was then incubated at 37 C for 1 hour. The media were decanted off and 100 μL of isopropyl alcohol was added to each well followed by shaking for 1 hour to dissolve the formed formazan crystals. The colour intensity in each well was measured at a wavelength of 550 nm. The percentage of cell viability was calculated relative to control wells, which were designated as 100% viable cells.
| Protein extraction and western blotting
Cells were grown in 6-well plates and subjected to the treatments outlined above. Cells were harvested in lysis buffer containing 20 mm Tris, 5 mM ethylenediaminetetraacetic acid (EDTA), 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 1% NP-40 and supplemented with protease and phosphatase inhibitor cocktails. The total cell homogenate was prepared and the protein concentration was measured by the Pierce BCA assay as described previously. 24 The cell homogenates (equivalent to 25 μg protein) were prepared in 6X sample buffer, boiled for 5 minutes, separated by 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. In order to confirm equal loading, membranes were stained for total protein using the MemCode Reversible Protein Stain Kit. Membranes were scanned and the protein stain was removed from the membranes as described in the kit instructions. Protein blots were blocked for 1 hour at room temperature in blocking buffer containing 5% skim milk powder and 0.05%
(vol/vol) Tween 20 in Tris-buffered saline solution (0.15 M sodium chloride, 3 mM potassium chloride and 25 mM Tris-base). After blocking, the blots were incubated with the specified primary antibody overnight at 4 C. Thereafter, the membranes were washed and incubated with a peroxidase-conjugated secondary antibody in blocking buffer for 1 hour at room temperature. The immune complex was visualized using the Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA). Thereafter, the blots were stripped for 45 minutes in stripping buffer (62.5 mM Tris, 2% SDS, 18 mM 2-mercaptoethanol, pH 6.7) at 50 C, washed, then blocked and probed as previously described. The intensity of protein bands was quantified using ImageJ software (National Institutes of Health, Bethesda, MD).
| Statistical analysis
Data are presented as mean AE standard error of the mean (SEM).
Data were checked for normality using the Shapiro-Wilk normality test. Comparisons between control and treatments were performed using a one-way analysis of variance (ANOVA), with a Bonferroni post hoc test. A probability value of <.05 is considered significant. 
| Resveratrol does not increase doxorubicininduced toxicity in H9c2 cells
Since a main adverse effect of doxorubicin therapy is cardiotoxicity, we determined whether resveratrol alters the toxic effect of doxorubicin in the cardiac-derived H9c2 cells. H9c2 cells were cultured in the presence or absence of increasing resveratrol concentrations for 2 hours; thereafter, the cells were co-treated with 1 μM doxorubicin for an additional 22 hours. Cell viability was determined by the MTT assay as described in Section 2. MTT assay has been widely used to assess doxorubicin-induced toxicity in H9c2 cardiomyoblasts. [25] [26] [27] [28] In contrast to HSA cells, resveratrol did not increase the toxicity of doxorubicin in the cardiac-derived H9c2 cells ( Figure 7 ).
| DISCUSSION
Resveratrol is a non-flavonoid polyphenolic phytochemical which possesses a plethora of biological effects. 7 A significant body of evidence suggests that resveratrol has anticancer and chemopreventive properties. 29 It has been shown to have both anti-proliferative and apoptotic properties resulting in a strong growth-inhibitory effect in multiple human cancer cell lines in vitro. 8, 9, 30 It has also been shown to inhibit tumour growth of several xenograft models of human cancers in vivo. 31, 32 Nevertheless, its anticancer effects have rarely been oral doses of 600 to 1200 mg/kg/day administered to beagle dogs, 33 suggesting a translational potential of our current findings. In this safety study, no treatment-related mortality or clinical signs of toxicity were observed after 13 weeks of resveratrol administration with no changes in histopathology or organ weights. However, there was a significant decrease in body weight due to decreased food consumption, and an increase in inflammatory infiltrates in the urinary bladders and kidney in dogs receiving 1200 mg/day. 33 To explore the mechanism of this growth-inhibitory effect, we measured the expression of the apoptotic marker, cleaved caspase-3.
Similar to previous findings in human cancer cells, 34 we demonstrate that resveratrol induces apoptosis in both Frog and DD-1 canine HSA cells, suggesting that apoptosis plays a significant role in mediating the growth-inhibitory effect of resveratrol in these cells. A limitation of the current study is the dependence on cleaved caspase-3 as the only apoptotic marker. Additional assays could have been used to verify the late stages of apoptosis, for example, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay.
In an attempt to elucidate the molecular mechanisms of the observed pro-apoptotic effect, we determined the effect of resveratrol on the key signalling pathways, p38 MAPK, AMPK and ERK1/2. The p38
MAPK is a key player in the regulation of apoptosis, cell cycle arrest and growth inhibition. 35 The anticancer effects of resveratrol have been shown to be mediated through p38 MAPK activation in several human cancer cell lines including: colon cancer, 32 chronic myelogenous leukaemia 36 and acute lymphoblastic leukaemia cells. shown to mediate survival in human cancer cells. 37, 42, 43 While some studies demonstrated that resveratrol inhibits ERK1/2 in Panc-1 human pancreatic cancer cells 44, 45 and SW620 human colon cancer cells, 46 another study showed that resveratrol activates ERK1/2 in MDA-231 breast cancer cells. 47 Interestingly, Hogg et al showed a biphasic effect of resveratrol on ERK1/2, wherein a low resveratrol concentration (10 μM) activated ERK1/2, whereas higher concentrations (50-100 μM) inhibited it. 48 In the current study, resveratrol (10-100 μM) had no effect on ERK1/2 in HSA cells, suggesting that the effect of resveratrol on ERK1/2 is concentration and cell typedependent.
Doxorubicin-based chemotherapy is the most effective adjuvant therapy for canine HSAs. 2 Of interest, resveratrol has been shown to augment the chemotherapeutic effect of doxorubicin in human cancer cell lines in vitro 49 and in mouse xenografts of human tumour in vivo. 50 However, the combined effect of resveratrol and doxorubicin in canine cancer cells has never been determined. Therefore, in the current work, we determined the growth inhibitory effect of resveratrol co-treatment with doxorubicin in canine HSA cells. We demonstrate that resveratrol enhances doxorubicin-induced cytotoxicity in both Frog and DD-1 cells. We also demonstrate that resveratrol markedly increases doxorubicin-induced apoptosis in these cells. It is interesting to note that in human breast cancer cells, resveratrol has been shown to down-regulate the expression of P-glycoprotein and multi-drug resistance protein, thus increasing doxorubicin accumulation in cancer cells. 50, 51 Further research is required to explore the possible role of these proteins in mediating the effect of resveratrol in canine HSA cells.
Since cardiotoxicity is a major adverse effect of doxorubicin, 52 we tested whether combining resveratrol with doxorubicin would alter its cardiotoxic effects. We used the rat-derived H9c2 cardiomyoblasts to determine the effect of resveratrol on doxorubicininduced cardiotoxicity. H9c2 cell line is a common in vitro model to study the cardiotoxic effects of doxorubicin. 53 While resveratrol has been shown to increase doxorubicin-induced cytotoxicity in cancer cells, it has been demonstrated to protect against doxorubicininduced cardiotoxicity both in vitro 54 and in vivo. 55 In the current work, we demonstrate that resveratrol did not increase the cardio- 
